Mission Statement

To understand how brain tumors develop in children and identify personalized treatment strategies.

About PNOC

The Pacific Pediatric Neuro-Oncology Consortium (PNOC) was formed to provide children with brain tumors access to innovative treatments. What sets us apart is that we pursue clinical strategies that are based on the molecular and genetic make-up of each tumor. We test therapies aimed at interfering with specific cellular pathways or mutations after confirming that a patient’s tumor has those characteristics, sparing patients therapy that is not optimized for their tumor type. 

The teams at each of PNOC’s 15 participating hospitals are made up of specialists in different areas of pediatric brain tumor treatment – such as oncology, neurosurgery, and radiation therapy – who combine their expertise to optimize care for each patient. The teams also include nurses, social workers, and hospital staff with an in-depth understanding of the needs of families and children suffering from brain tumors. Finally, each site has scientists actively engaged in laboratory research on pediatric tumor biology who work with clinicians to turn their findings into therapies.

PNOC Scientific Committee

The Scientific Committee consists of designated key physicians and laboratory investigators at each of the Member Institutions. The goal of the Scientific Committee is to advise and assist in setting the scientific strategy of the PNOC. The members of the Scientific Committee play a critical role in developing the translational agenda, and assist and conduct pre‐clinical and laboratory studies as needed to support the development of study concepts and/or correlative studies linked to specific PNOC clinical trials.

  • 98 Pediatric Brain Tumor Specialists
  • 5 active clinical trials
  • 15 participating
  • PI Spotlight

    Joseph Torkildson, MD
    Pediatric Neuro-oncologist
    Dr. Joseph Torkildson is the director of pediatric neuro-oncology at Children's Hospital & Research Center Oakland. He has a special interest in developing alternative therapies that will allow the avoidance of radiation therapy in the youngest children with malignant brain tumors.